Download EMEA User Guide for SMEs

Transcript
1.1 Obtaining a marketing authorisation within the European Union
Prior to marketing a medicinal product in the EU, a marketing authorisation (product
licence) must be obtained. The company responsible for placing the medicinal product
on the market (so-called marketing authorisation holder) must be "established" 2 within
the EEA (Iceland, Liechtenstein, Norway and the Member States of the European Union).
In the EU, there are two types of marketing authorisation:
National marketing authorisations
issued by the competent authorities of
individual Member States. The medicinal
product may be put on the market in all
Member States that have granted
an authorisation for it.
or
Community marketing authorisation
granted by the European Commission,
following a positive opinion from the EMEA.
This is a single authorisation that
allows the medicinal product to be put
on the market in all Member States.
Approved conditions of use are laid down in the summary of product characteristics 3
(prescribing information for health professionals), the labelling and the package leaflet
for users 4 .
This user guide will focus on the use of the centralised procedure for obtaining a
Community marketing authorisation. Further information on the regulatory routes for
obtaining national marketing authorisations, namely the mutual recognition and
decentralised procedure, are highlighted in Section 1.1.2 below. Applicants are advised
to refer to the Notice to Applicants, Volume 2A and Volume 6A – Procedures for
marketing authorisation 5 , for more detailed information.
1.1.1
Community marketing authorisation – the centralised procedure
The European Medicines Agency
coordinates the existing scientific
resources of the Member States in to
evaluate and supervise medicinal
products for both human and
veterinary
use
throughout
the
European Union. The EMEA is
primarily involved in the centralised
procedure for obtaining a Community
marketing authorisation.
For queries relating to: orphan designation,
paediatric
investigation
plans,
pan-European
scientific advice, filing an application for marketing
authorisation through the centralised procedure, and
EudraVigilance, the EMEA is the primary point of
contact.
If an SME has any doubt about the appropriate point
of contact for a particular issue, the SME Office can
provide assistance: [email protected]
The agency also gives scientific advice to research-based companies in the development
stage of new medicinal products (see Section 3.1) and develops guidelines on quality,
safety and efficacy testing requirements (see Section 3.2).
2
Being established, here, means having a permanent legal structure (formed in accordance with the law of an EU Member
State or other EEA country) that allows the concerned person to assume the duties and responsibilities as well as to
perform the tasks laid down by Community law, see Annex II of Chapter I, Vol. 2A (human medicines) or 6A (veterinary
medicines) of the Notice to Applicants http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/index.htm .
3
In accordance with Article 11 of Directive 2001/83/EC for human medicines and Article 14 of Directive 2001/82/EC for
veterinary medicines.
4
In accordance with Articles 54, 55, 59 and 63 of Directive 2001/83/EC for human medicines and Articles 58-61 for
veterinary medicines.
5
Published on the European Commission’s Pharmaceuticals website:
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/eudralex_en.htm
© EMEA 2009
5/69